CN117460511A - 含有二氢哒嗪-3,5-二酮衍生物的制剂 - Google Patents

含有二氢哒嗪-3,5-二酮衍生物的制剂 Download PDF

Info

Publication number
CN117460511A
CN117460511A CN202280041019.3A CN202280041019A CN117460511A CN 117460511 A CN117460511 A CN 117460511A CN 202280041019 A CN202280041019 A CN 202280041019A CN 117460511 A CN117460511 A CN 117460511A
Authority
CN
China
Prior art keywords
pharmaceutical composition
weight
less
formula
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280041019.3A
Other languages
English (en)
Chinese (zh)
Inventor
酒井宪一
内山博雅
蓑田知幸
吉川真由美
夏本盛森
高野隆介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117460511A publication Critical patent/CN117460511A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280041019.3A 2021-06-08 2022-06-08 含有二氢哒嗪-3,5-二酮衍生物的制剂 Pending CN117460511A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-096206 2021-06-08
JP2021096206 2021-06-08
PCT/JP2022/023076 WO2022260064A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Publications (1)

Publication Number Publication Date
CN117460511A true CN117460511A (zh) 2024-01-26

Family

ID=84426023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280041019.3A Pending CN117460511A (zh) 2021-06-08 2022-06-08 含有二氢哒嗪-3,5-二酮衍生物的制剂

Country Status (12)

Country Link
US (1) US20240293402A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353233A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022260064A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240018523A (cg-RX-API-DMAC7.html)
CN (1) CN117460511A (cg-RX-API-DMAC7.html)
AU (1) AU2022288895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221186A1 (cg-RX-API-DMAC7.html)
IL (1) IL309056A (cg-RX-API-DMAC7.html)
MX (1) MX2023014507A (cg-RX-API-DMAC7.html)
TW (1) TW202317118A (cg-RX-API-DMAC7.html)
WO (1) WO2022260064A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073715A (zh) * 2013-03-13 2015-11-18 中外制药株式会社 二氢哒嗪-3,5-二酮衍生物
WO2016039458A1 (ja) * 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬
CN112533608A (zh) * 2018-09-03 2021-03-19 正大天晴药业集团股份有限公司 包含 1,3,5-三嗪衍生物或其盐的固体药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
US9499553B2 (en) * 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
MX376202B (es) 2016-08-15 2025-03-07 Lilly Co Eli Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073715A (zh) * 2013-03-13 2015-11-18 中外制药株式会社 二氢哒嗪-3,5-二酮衍生物
WO2016039458A1 (ja) * 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬
CN112533608A (zh) * 2018-09-03 2021-03-19 正大天晴药业集团股份有限公司 包含 1,3,5-三嗪衍生物或其盐的固体药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALLANT, KMH ET AL.: "EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients", KIDNEY INTERNATIONAL, vol. 99, no. 5, 24 May 2021 (2021-05-24), pages 1225 - 1233 *
TSUBOI, Y ET AL.: "EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder", KIDNEY INTERNATIONAL, vol. 98, no. 2, 12 August 2020 (2020-08-12), pages 343 - 354 *

Also Published As

Publication number Publication date
KR20240018523A (ko) 2024-02-13
MX2023014507A (es) 2024-01-26
EP4353233A1 (en) 2024-04-17
BR112023023708A2 (pt) 2024-01-30
AU2022288895A1 (en) 2024-01-18
US20240293402A1 (en) 2024-09-05
IL309056A (en) 2024-02-01
TW202317118A (zh) 2023-05-01
WO2022260064A1 (ja) 2022-12-15
JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2022-12-15
EP4353233A4 (en) 2025-06-25
CA3221186A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
TWI325318B (en) Capsule and method of manufacturing the same
BG64691B1 (bg) Зипрасидонови препарати
TW201531309A (zh) N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物
KR101352130B1 (ko) 디클로페낙 제제 및 이용 방법
CA2919522A1 (en) Formulation of syk inhibitors
TW202317136A (zh) 穩定之伐尼克蘭劑型
EP3525792A1 (en) Powder for oral suspension containing lamotrigine
US10583087B2 (en) Pharmaceutical composition for oral administration
JP2022524424A (ja) 向上したバイオアベイラビリティを有する化合物形態及びその製剤
JP2008044960A (ja) 経口固形医薬
WO2021216545A1 (en) Oral solid meloxicam formulations for the treatment of acute pain
WO2022260064A1 (ja) ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤
HK40104119A (en) Formulation containing dihydropyridazine-3,5-dione derivative
Thompson et al. Can the oral bioavailability of the discontinued prostate cancer drug galeterone Be improved by processing method? KinetiSol® outperforms spray drying in a head-to-head comparison
JP7109255B2 (ja) 粉砕物の製造方法及び錠剤の製造方法
EP3162368A1 (en) Pharmaceutical composition for oral administration
JP7820568B2 (ja) 溶出性及び打錠性に優れた製剤
Munnangi Advancing Pharmaceutical Manufacturing: Innovative Applications of Hot Melt Extrusion for the Preparation of Drug Complexes and Fixed Dose Combination Immediate Release Formulation with Diverse Crystalline Properties
EP4059504A1 (en) Drug substance of lemborexant and medicinal composition comprising same
EP4721739A1 (en) Csf-1r inhibitor pharmaceutical composition, preparation method therefor and pharmaceutical use thereof
TW202448468A (zh) 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
TW202333702A (zh) 具有優異溶出性之醫藥組成物
HK40051811A (en) Diclofenac formulations and methods of use
CA3166050A1 (en) Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40104119

Country of ref document: HK